1-5 of 5
Ying Luan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

John C. Byrd, MD, Richard R. Furman, MD, Steven Coutre, MD, Ian W. Flinn, MD PhD, Jan A. Burger, MD PhD, Kristie A. Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Ying Luan, PhD, Emily A. Liu, PhD, James P. Dean, MD PhD, Susan M. O'Brien, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3133.
https://doi.org/10.1182/blood-2018-99-110847
Published: 2018
Journal Articles

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Clinical Trials & Observations
Susan O’Brien, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, William Wierda, Jeffrey Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, John C. Byrd
Journal: Blood
Blood (2018) 131 (17): 1910–1919.
https://doi.org/10.1182/blood-2017-10-810044
Published: 2018
Includes: Supplemental data
Journal Articles

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Susan M. O'Brien, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Ian W. Flinn, MD PhD, Jan Burger, MD PhD, Kristie Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Jeffrey Jones, MD MPH, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Ying Luan, PhD, Danelle F. James, MD MAS, Alvina D. Chu, MD, John C. Byrd, MD
Journal: Blood
Blood (2016) 128 (22): 233.
https://doi.org/10.1182/blood.V128.22.233.233
Published: 2016
Journal Articles

Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study

Vincent Ribrag, MD, Won Seog Kim, MD PhD, Reda Bouabdallah, MD, Soon Thye Lim, MBBS, MRCP, Bertrand Coiffier, Zakia Felloussi, Ioana Kloos, Ying Luan, PhD, Thorsten Graef, MD PhD, Franck Morschhauser, MD
Journal: Blood
Blood (2015) 126 (23): 256.
https://doi.org/10.1182/blood.V126.23.256.256
Published: 2015
Journal Articles

A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Andrew M. Evens, DO, MSc, Julie M Vose, MD, MBA, Wael Harb, MD, Leo I. Gordon, MD, Robert Langdon, MD, Barbara Grant, MD, Julian Sprague, MD, PhD, Clara Plasencia, MS, Mint Sirisawad, MS, Jeanne Yue, MS, Ying Luan, PhD, Aaron Siek, BS, Lei Zhou, MD, Sriram Balasubramanian, PhD, Nancy L. Bartlett, MD
Journal: Blood
Blood (2012) 120 (21): 55.
https://doi.org/10.1182/blood.V120.21.55.55
Published: 2012